• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4-20 ng/mL.一种用于预测前列腺特异性抗原(PSA)水平在4-20 ng/mL的患者患前列腺癌的、带有凝血标志物的列线图。
Future Oncol. 2025 Feb;21(4):463-471. doi: 10.1080/14796694.2024.2445499. Epub 2024 Dec 23.
2
Multicenter External Validation and Optimization of a Proposed Nomogram for Prostate-Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence.多中心外部验证及对前列腺特异性膜抗原PET/CT在生化复发中准确性的拟用列线图的优化
Prostate. 2025 Aug;85(11):1016-1023. doi: 10.1002/pros.24910. Epub 2025 May 6.
3
A strategy to reduce unnecessary prostate biopsies in patients with tPSA >10 ng ml -1 and PI-RADS 1-3.一项针对总前列腺特异抗原(tPSA)>10 ng/ml且前列腺影像报告和数据系统(PI-RADS)为1-3级患者减少不必要前列腺活检的策略。
Asian J Androl. 2025 Jul 1;27(4):531-536. doi: 10.4103/aja202499. Epub 2025 Jan 28.
4
The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review.仅使用前列腺特异性抗原预测前列腺活检阳性风险的模型的可比性:一项系统综述。
Eur Urol. 2008 Aug;54(2):274-90. doi: 10.1016/j.eururo.2008.05.022. Epub 2008 May 22.
5
Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.基于磁共振成像时代下前列腺特异性抗原密度对临床显著前列腺癌的诊断性能:系统评价和荟萃分析。
Eur Urol Oncol. 2024 Apr;7(2):189-203. doi: 10.1016/j.euo.2023.08.002. Epub 2023 Aug 26.
6
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
7
Development and Validation of a Predictive Model of Prostate Screening Compliance: A Nationwide Population-Based Study.前列腺筛查依从性预测模型的开发与验证:一项基于全国人口的研究。
Prostate. 2025 May;85(6):513-523. doi: 10.1002/pros.24854. Epub 2025 Jan 13.
8
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial.在一个种族和民族多样化队列中比较Stockholm3、血清生物标志物和风险计算器对前列腺癌的预测:Stockholm3多民族SEPTA试验的评估
J Urol. 2025 May;213(5):590-599. doi: 10.1097/JU.0000000000004437. Epub 2025 Apr 9.
9
A novel nomogram for predicting osteoporosis with low back pain among the patients in Wenshan Zhuang and Miao Autonomous Prefecture of China.中国文山壮族苗族自治州患者中用于预测伴有腰痛的骨质疏松症的新型列线图。
Front Endocrinol (Lausanne). 2025 Jun 5;16:1535163. doi: 10.3389/fendo.2025.1535163. eCollection 2025.
10
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.

本文引用的文献

1
Periprostatic Adipose Tissue: A New Perspective for Diagnosing and Treating Prostate Cancer.前列腺周围脂肪组织:诊断和治疗前列腺癌的新视角。
J Cancer. 2024 Jan 1;15(1):204-217. doi: 10.7150/jca.89750. eCollection 2024.
2
Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.基于 PI-RADS v2.1,结合 PHI 和 ADC 值指导 PSA 为 4-20ng/mL 的患者进行前列腺活检。
Prostate. 2024 Mar;84(4):376-388. doi: 10.1002/pros.24658. Epub 2023 Dec 20.
3
Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.停止有组织的筛查后老年男性前列腺癌死亡率:来自鹿特丹前列腺癌筛查欧洲随机研究的长期结果
Eur Urol. 2024 Jan;85(1):74-81. doi: 10.1016/j.eururo.2023.10.011. Epub 2023 Oct 31.
4
Development and internal validation of a nomogram predicting significant prostate cancer: Is it clinically applicable in low prevalent prostate cancer countries? A multicenter study.列线图预测前列腺癌意义的开发和内部验证:在前列腺癌低发国家具有临床适用性吗?一项多中心研究。
Prostate. 2024 Jan;84(1):56-63. doi: 10.1002/pros.24625. Epub 2023 Sep 27.
5
The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer.前列腺疾病中慢性炎症的分子基础及临床后果:前列腺炎、良性前列腺增生和前列腺癌。
Cancers (Basel). 2023 Jun 8;15(12):3110. doi: 10.3390/cancers15123110.
6
Diagnostic Efficiency of Pan-Immune-Inflammation Value to Predict Prostate Cancer in Patients with Prostate-Specific Antigen between 4 and 20 ng/mL.全免疫炎症值对前列腺特异性抗原在4至20 ng/mL之间的患者预测前列腺癌的诊断效能
J Clin Med. 2023 Jan 19;12(3):820. doi: 10.3390/jcm12030820.
7
Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4-20 ng/mL.基于活检前 bpMRI 和血液学参数的风险评分模型,预测 PSA 4-20ng/mL 范围内的活检初筛阴性男性的预后。
Sci Rep. 2022 Dec 19;12(1):21895. doi: 10.1038/s41598-022-26242-7.
8
MRI determined prostate volume and the incidence of prostate cancer on MRI-fusion biopsy: a systemic review of reported data for the last 20 years.MRI测定的前列腺体积与MRI融合活检中前列腺癌的发病率:对过去20年报告数据的系统评价
Int Urol Nephrol. 2022 Dec;54(12):3047-3054. doi: 10.1007/s11255-022-03351-w. Epub 2022 Aug 30.
9
The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis.全免疫炎症值与癌症预后的关联:一项系统评价与荟萃分析
Cancers (Basel). 2022 May 27;14(11):2675. doi: 10.3390/cancers14112675.
10
Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection.改良前列腺健康指数密度显著提高临床显著性前列腺癌(csPCa)的检测率。
Front Oncol. 2022 Apr 7;12:864111. doi: 10.3389/fonc.2022.864111. eCollection 2022.

一种用于预测前列腺特异性抗原(PSA)水平在4-20 ng/mL的患者患前列腺癌的、带有凝血标志物的列线图。

A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4-20 ng/mL.

作者信息

Liu Feifan, Wang Jianyu, Song Yufeng, Wu Fei, Wu Haihu, Lyu Jiaju, Ning Hao

机构信息

Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, P.R. China.

Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, P.R. China.

出版信息

Future Oncol. 2025 Feb;21(4):463-471. doi: 10.1080/14796694.2024.2445499. Epub 2024 Dec 23.

DOI:10.1080/14796694.2024.2445499
PMID:39711215
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11812327/
Abstract

BACKGROUND

The global incidence of prostate cancer (PCa) is rising, necessitating improved diagnostic strategies. This study explores coagulation parameters' predictive value for clinically significant PCa (csPCa) and develops a nomogram.

RESEARCH DESIGN AND METHODS

This study retrospectively analyzed data from 702 patients who underwent prostate biopsy at Shandong Provincial Hospital (SDPH) and 142 patients at Shandong Cancer Hospital and Institute (SDCHI). SDPH patients were randomly assigned at a 7:3 ratio for internal validation, while SDCHI data served as external validation. LASSO and logistic regression identified the best predictive factors for csPCa, which were used to construct a model. The model's efficacy was tested using AUC, calibration curves, and decision curve analysis.

RESULTS

TPSA, age, D-dimer, prostate volume (PV), and digital rectal examination (DRE) were identified as independent risk factors for csPCa. A predictive model was constructed using a nomogram. The AUC for the training set was 0.841, for internal validation 0.809, and for external validation 0.814. Calibration and decision curves confirmed the model's clinical utility.

CONCLUSIONS

The nomogram incorporating D-dimer, TPSA, age, PV, and DRE provides a highly accurate tool for assessing csPCa risk in individuals with PSA levels of 4-20 ng/mL, supporting personalized diagnostics and clinical decision-making.

摘要

背景

前列腺癌(PCa)的全球发病率正在上升,因此需要改进诊断策略。本研究探讨凝血参数对临床显著性前列腺癌(csPCa)的预测价值,并开发一种列线图。

研究设计与方法

本研究回顾性分析了山东省立医院(SDPH)702例接受前列腺活检患者以及山东省肿瘤医院暨山东省肿瘤防治研究院(SDCHI)142例患者的数据。SDPH患者按7:3的比例随机分配用于内部验证,而SDCHI的数据用作外部验证。LASSO和逻辑回归确定了csPCa的最佳预测因素,并用于构建模型。使用AUC、校准曲线和决策曲线分析对模型的有效性进行了测试。

结果

总前列腺特异性抗原(TPSA)、年龄、D-二聚体、前列腺体积(PV)和直肠指检(DRE)被确定为csPCa的独立危险因素。使用列线图构建了一个预测模型。训练集的AUC为0.841,内部验证为0.809,外部验证为0.814。校准曲线和决策曲线证实了该模型的临床实用性。

结论

包含D-二聚体、TPSA、年龄、PV和DRE的列线图为评估总前列腺特异性抗原水平在4-20 ng/mL的个体发生csPCa的风险提供了一种高度准确的工具,支持个性化诊断和临床决策。